24/04/2014 21:02:33 Free Membership Login

Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
03/19/20148:00AMPRNUSHealthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Or...
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 19, 2014 NEW YORK, March 19, 2014 /PRNewswire/ -- Today, Analysts... More...>>
03/06/201412:22PMPRNUSTechnical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia PR Newswire NEW YORK, March 6, 2014 NEW YORK, March 6, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The trading session on Wednesday, March 05, 2014 ended on a mixed note as the Dow Jones Industrial... More...>>
03/04/20144:57PMGLOBEXOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
BERKELEY, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights and financial results for the fourth quarter and year ended December 31, 2013. 2013 Operational Highlights Announced the selection... More...>>
03/04/20144:36PMGLOBEXOMA Provides Update on Gevokizumab Proof-of-Concept Program
Results from two Phase 2 erosive osteoarthritis of the hand studies do not support movement to pivotal development FDA End of Phase 2 meeting for pyoderma gangrenosum indication scheduled for March 2014 Conference call to be held today at 6:00 p.m. Eastern / 3:00 p.m. Pacific BERKELEY, Calif., March 4, 2014 (GLOBE NEWSWIRE... More...>>
02/24/20146:20PMGLOBEXOMA Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum
BERKELEY, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today gevokizumab, the Company's IL-1 beta modulating antibody, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for... More...>>
01/14/20148:52AMZACKSSurging Earnings Estimates Signal Good News for XOMA Corporation (XOMA) - Tale of the Tape
Xoma Corporation (XOMA) is a developer of antibody-based therapeutics that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest... More...>>
12/18/20134:01PMGLOBEXOMA Announces Closing of the Offering and Exercise of Option
BERKELEY, Calif., Dec. 18, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today the closing of the offering of 10,925,000 shares of its common stock, including 1,425,000 shares of common stock that were issued upon the exercise in full of the underwriters' option to purchase additional shares, at a price... More...>>
12/13/20139:13AMGLOBEXOMA Announces Pricing of Approximately $50.0 Million Offering of Common Stock
BERKELEY, Calif., Dec. 13, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today the pricing of 9,500,000 shares of its common stock at a price to the public of $5.25 per share. In addition, XOMA has granted the underwriters a 30-day option to purchase up to an additional 1,425,000 shares of... More...>>
12/12/20134:05PMGLOBEXOMA Announces Proposed Public Offering of Common Stock
BERKELEY, Calif., Dec. 12, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. XOMA also expects to grant the underwriters... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
11/26/20131:00PMGLOBEXOMA to Present at the Piper Jaffray Healthcare Conference
BERKELEY, Calif., Nov. 26, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the company's Chief Executive Officer, is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on December 4, 2013... More...>>
11/20/20139:00AMGLOBEXOMA Awarded Key Flexible Manufacturing Patent
BERKELEY, Calif., Nov. 20, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that the United States Patent and Trademark Office has awarded it U.S. patent no. 8,584,349, entitled "Flexible Manufacturing System." This patent relates... More...>>
11/15/20138:39AMDJNKingdon Capital Management 3Q 13F: Largest Purchases
DJ CFA SOURCE: SEC 13F-HR FILER: Kingdon Capital Management LLC QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest purchases of Kingdon Capital Management LLC are listed below, ordered by the number of shares bought during the three months ended Sep. 30. Company Name Value Holdings Change CANADIAN... More...>>
11/15/20138:39AMDJNKingdon Capital Management 3Q 13F: Holdings As Of -2-
OWENS CORNING COM $1,899,000 50,000 50,000 * KOHLS CORP COM $1,811,250 35,000 35,000 * ENANTA PHARMACEUTICALS INC CO $1,719,000 75,000 0 ISHARES MSCI MEXICO CAPPED ETF $1,597,250 25,000 25,000 * STRYKER CORP COM $1,514,016 22,400 0 SOLAZYME INC COM $1,314,152 121,850 0 IMPAX LABORATORIES INC COM $1,125,850 55,000 (105,000... More...>>
11/15/20138:39AMDJNKingdon Capital Management 3Q 13F: Holdings As Of Sep 30
DJ CFA SOURCE: SEC 13F-HR FILER: Kingdon Capital Management LLC QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 The following sets forth up to 200 of the largest holdings of Kingdon Capital Management LLC as of Sep. 30, according to a Form 13F filed with the Securities and Exchange Commission. As of Sep. 30, Kingdon... More...>>
11/15/20138:22AMDJNJanus Capital Management 3Q 13F: Largest Purchases -2-
STANDARD PARKING CORP COM $55,745,955 2,073,111 37,128 RED HAT INC COM $9,827,912 213,002 33,229 ICICI BANK LTD ADR $1,962,912 64,400 31,713 W W GRAINGER INC COM $206,623,447 789,513 30,944 SYNAGEVA BIOPHARMA CORP COM $79,011,155 1,246,390 29,468 BBVA BANCO FRANCES SA ADR $192,953 29,103 29,103 CTPARTNERS EXECUTIVE SEARCH... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq xoma140424 21:02